文献速递食管胃疾病与幽门螺杆菌

伏诺拉生作为糜烂性食管炎长期维持治疗:VISION 五年随机开放标签研究

Vonoprazan as a Long-term Maintenance Treatment for Erosive Esophagitis: VISION, a 5-Year, Randomized, Open-label Study.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-08-27

这项IV期随机开放标签研究纳入208例糜烂性食管炎患者,诱导治疗后202例愈合者接受伏诺拉生10 mg或兰索拉唑15 mg维持治疗260周(2:1)。伏诺拉生组壁细胞增生(97.1% vs 86.5%)和胃小凹增生(14.7% vs 1.9%)比例更高,中位血清胃泌素更高(625 pg/mL vs 200 pg/mL);两组均无恶性上皮细胞改变或胃神经内分泌肿瘤,不良事件发生率相当。

要点

  • 伏诺拉生组壁细胞增生97.1%,高于兰索拉唑组86.5%。
  • 伏诺拉生组胃小凹增生14.7%,高于兰索拉唑组1.9%。
  • 两组均无恶性上皮细胞改变或胃神经内分泌肿瘤,各有1例腺瘤。

核心结论

  • 伏诺拉生组胃泌素浓度、壁细胞增生和胃小凹增生高于兰索拉唑组,但恶性上皮细胞改变和胃神经内分泌肿瘤风险未增加。

研究设计与样本

  • IV期随机开放标签探索性研究,纳入糜烂性食管炎患者,诱导治疗(伏诺拉生20 mg或兰索拉唑30 mg每日一次,≤8周)后愈合者接受维持治疗(伏诺拉生10 mg或兰索拉唑15 mg每日一次)260周,按2:1随机分组。
  • 202/208例患者(伏诺拉生组n=139,兰索拉唑组n=69)达到糜烂性食管炎愈合并接受维持治疗。

主要发现

  • 未观察到恶性上皮细胞改变或胃神经内分泌肿瘤,两组各1例腺瘤。
  • 第260周时,伏诺拉生组壁细胞增生比例显著高于兰索拉唑组(97.1% vs 86.5%)。
  • 第260周时,伏诺拉生组胃小凹增生比例显著高于兰索拉唑组(14.7% vs 1.9%)。
  • 第260周时,两组肠嗜铬样细胞增生比例(4.9% vs 7.7%)和G细胞增生比例(85.3% vs 76.9%)相似。
  • 伏诺拉生组中位血清胃泌素水平高于兰索拉唑组(625 pg/mL vs 200 pg/mL)。

关键数值与推荐

  • 主要终点为恶性上皮细胞改变、壁细胞增生、胃小凹增生、肠嗜铬样细胞增生和G细胞增生的患者比例。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Acid secretion inhibitors are associated with hypergastrinemia, which can lead to gastric mucosal changes. Potassium-competitive acid blockers, such as vonoprazan, are more potent than proton pump inhibitors, but long-term safety data are lacking. METHODS: In this phase IV, randomized trial, patients with erosive esophagitis (EE) received induction therapy (once daily vonoprazan 20 mg or lansoprazole 30 mg; ≤8 weeks). Those with healed EE received maintenance therapy (once daily vonoprazan 10 mg or lansoprazole 15 mg) for 260 weeks (2:1). The primary endpoint was the proportion of patients with malignant epithelial cell alterations, parietal cell hyperplasia, foveolar hyperplasia, enterochromaffin-like (ECL) cell hyperplasia, and G-cell hyperplasia. RESULTS: Overall, 202/208 patients (vonoprazan, n = 139; lansoprazole, n = 69) achieved healed EE and received maintenance therapy. No malignant alterations or gastric neuroendocrine tumors (NETs) were observed; there was 1 adenoma in each group. At week 260, significantly more patients taking vonoprazan vs lansoprazole had parietal cell hyperplasia (97.1% vs 86.5%) and foveolar hyperplasia (14.7% vs 1.9%); proportions of patients with ECL cell hyperplasia (4.9% vs 7.7%) and G-cell hyperplasia (85.3% vs 76.9%) were similar. Median serum gastrin levels were higher with vonoprazan treatment vs lansoprazole (625 pg/mL vs 200 pg/mL). Incidences of adverse events were comparable for both treatments. CONCLUSIONS: The exploratory VISION study assessed the safety profile of vonoprazan and lansoprazole over 5 years in Japanese patients with healed EE. Although gastrin concentration, parietal cell hyperplasia, and foveolar hyperplasia were higher in the vonoprazan group, there was no increased risk of malignant epithelial cell alterations and gastric NETs. (ClinicalTrials.gov, NCT02679508).

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Uemura N, Kinoshita Y, Haruma K, et al. Vonoprazan as a Long-term Maintenance Treatment for Erosive Esophagitis: VISION, a 5-Year, Randomized, Open-label Study. Clin Gastroenterol Hepatol. 2024. PMID: 39209187. doi:10.1016/j.cgh.2024.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。